informa

ARTICLE

A modified low-cost colorimetric method for paracetamol (acetaminophen) measurement in plasma

FATHIMA SHIHANA^{1,2}, DHAMMIKA DISSANAYAKE^{1,2}, PAUL DARGAN^{3,4}, and ANDREW DAWSON^{1,5}

Background. Despite a significant increase in the number of patients with paracetamol poisoning in the developing world, plasma paracetamol assays are not widely available. The purpose of this study was to assess a low-cost modified colorimetric paracetamol assay that has the potential to be performed in small laboratories with restricted resources. *Methods*. The paracetamol assay used in this study was based on the Glynn and Kendal colorimetric method with a few modifications to decrease the production of nitrous gas and thereby reduce infrastructure costs. Preliminary validation studies were performed using spiked aqueous samples with known concentrations of paracetamol. Subsequently, the results from the colorimetric method for 114 stored clinical samples from patients with paracetamol poisoning were compared with those from the current gold-standard high-performance liquid chromatography method. A prospective survey, assessing the clinical use of the paracetamol assay, was performed on all patients with paracetamol poisoning attending the Peradeniya General Hospital, Sri Lanka, over a 10-month period. Results. The recovery study showed an excellent correlation ($r^2 > 0.998$) for paracetamol concentrations from 25 to 400 mg/L. The final yellow color was stable for at least 10 min at room temperature. There was also excellent correlation with the high-performance liquid chromatography method ($r^2 = 0.9758$). In the clinical cohort study, use of the antidote N-acetylcysteine was avoided in over a third of patients who had the plasma paracetamol concentration measured. The cost of consumables used per assay was \$0.50 (US). Conclusions. This colorimetric paracetamol assay is reliable and accurate and can be performed rapidly, easily, and economically. Use of this assay in resourcepoor clinical settings has the potential to have a significant clinical and economic impact on the management of paracetamol poisoning.

Keywords Acute poisoning; Acetaminophen; Acute renal failure; Analytical; Quantitative analysis

Introduction

Paracetamol is one of the most widely used analgesics/antipyretics worldwide. In patients presenting with paracetamol overdose, the current standard of care is to undertake a risk assessment based on measurement of the plasma paracetamol concentration and to compare this with a nomogram to establish the need for antidote treatment with N-acetylcysteine (NAC). In some circumstances, such as the absence of an assay service, risk assessment can be made on the history of the ingested dose; however, this generally leads to overtreatment of many patients who are at low risk of hepatotoxicity as there is a poor correlation between patients stated ingested dose of paracetamol and paracetamol concentration.^{2,3}

Received 25 September 2009; accepted 26 October 2009. Address correspondence to Fathima Shihana, Department of Pathology, Faculty of Medicine, University of Peradeniya, Peradeniya, Kandy 20000, Sri Lanka. E-mail: shihana@sactrc.org

In Sri Lanka, the incidence of paracetamol poisoning gradually increased over 5 years (2004–2008) from 2.8 to 6.4% (95% CI = 2.3–4.9; p < 0.001) (Abstract published in 8th APAMT). Although pesticide poisoning remains more common, paracetamol is now the most common drug in patients presenting with self-poisoning. Paracetamol poisoning is becoming more common in other areas of South Asia such as Nepal.4,5 In Sri Lanka and other areas of South Asia, laboratory facilities to determine plasma paracetamol concentrations are only available in a few private laboratories. As paracetamol assays are not widely available, risk assessment in patients presenting with paracetamol poisoning is based on the history of the dose ingested and this results in a significant proportion of individuals having unnecessary treatment with the antidote.^{6,7} The plasma paracetamol concentration is also important in patients admitted with paracetamol poisoning with an uncertain history and/or in individuals who have coingested agents that cause drowsiness.1

The aim of this study was to assess and validate a low-cost colorimetric paracetamol assay that has the potential to be



¹South Asian Clinical Toxicology Research Collaboration, University of Peradeniya, Peradeniya, Sri Lanka

²Department of Pathology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka

³Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁴King's Health Partners, London, UK

⁵School of Population Health, University of Newcastle, Newcastle, Australia

performed in small laboratories with restricted resources and to look at its impact on the management of a cohort of patients with paracetamol poisoning.

Materials and methods

Reagents

Trichloroacetic acid (C₂HCl₃O₂, MW 153.39), sodium nitrite (NaNO₂, MW 69.0), sodium hydroxide (NaOH, MW 40.0), sulfamic acid (NH₂SO₃H, MW 97.09), and hydrochloric acid (HCl, MW 36.46) were purchased from Sigma Chemicals (Sigma Aldrich, Taufkirchen, Germany). All reagents were of analytical grade. Paracetamol powder was used to prepare 1,000 mg/L stock solution that was prepared by dissolving powder in warm distilled water. The stock solution was used to prepare eight series of (25–500 mg/L) working standards: 25, 50, 100, 150, 200, 250, 300, 350, and 450 g/dL.

The colorimetric assay

The colorimetric method used was based on the Glynn and Kendal method with a few modifications (Table 1) to the volume of sample and reagents to decrease the production of nitrous gas. In the modified method, 0.5 mL of plasma was pipetted into a 15-mL centrifuge tube containing 1.0 mL of 15% trichloroacetic acid. After vortex mixing, it was centrifuged briefly for 3 min and the clear supernatant was decanted into a 10-mL test tube containing 0.5 mL 6N hydrochloric acid. Nitrous acid was generated by adding 0.4 mL of sodium nitrite to the resulted solution. After allowing the contents to stand for 2 min, 1.0 mL of 15% sulfamic acid was added carefully to neutralize excess nitrous acid. Finally, 2.5 mL of 15% sodium hydroxide was added and the absorbance of each sample was measured at 430 nm, against a reagent blank of water.

The validation experiments

A calibration curve was calculated using this method to measure standard paracetamol concentrations (25, 50, 100, 150, 200, 250, 300, and 400 mg/L) using a UV-visible spectrophotometer (Unico 2802). Within-run precision (CV) was evaluated by 14 different assays of paracetamol standards. The stability of the final colored solution was also assessed up to 10 min by measuring the absorbance (this was an end-point measurement rather than a kinetic one).

Comparison of the colorimetric assay with high-performance liquid chromatography

The plasma samples used in this part of the study were taken from 114 patients with paracetamol poisoning admitted to Galle and Peradeniya Hospitals in Sri Lanka. The samples were analyzed using the colorimetric assay and were then stored at -20°C and analyzed using a reference high-performance liquid chromatography (HPLC) method (Roche modular system; Roche Diagnostics, Mannheim, Germany) at Guy's and St Thomas' NHS Foundation Trust in London, UK.

Clinical study

A prospective survey was undertaken of all patients with paracetamol poisoning presenting to the Peradeniya General Hospital, Sri Lanka, over a 10-month period from March 2008 to January 2009. Ethical approval for this and the above studies was obtained from the Ethical Review Committee, University of Peradeniya, Sri Lanka. Patients with suspected paracetamol poisoning had a sample taken for a plasma concentration at the time of admission. Paracetamol levels were measured during the daytime only. Doctors were asked to use the plasma paracetamol concentration, the time since ingestion and the consensus nomogram used in Australia and New Zealand to guide treatment. When the plasma paracetamol assay was not available, commonly when the patient presented at nighttime, an ingested dose of greater than 200 mg/kg was used as the treatment threshold, and if the paracetamol concentration was subsequently found to be below the risk level, the NAC infusion was ceased.

Results

The colorimetric paracetamol assay validation studies in aqueous solution were found to perform well up to a concentration of 400 mg/L ($r^2 = 0.998$); Fig. 1 shows the calibration plot for the standard paracetamol solutions and correlation coefficient for the calibration curve. The coefficient variant and accuracy for interbatch standards were 1.1 and 0.21%,

Table 1. Modification of Glynn and Kendal colorimetric method

	Glynn and Kendal colorimetric method (mL)	Modification in proposed method (mL)
Amount of sample	1.00	0.5
Trichloroacetic acid	2.00	1.00
6N hydrochloric acid	0.50	0.5
Sodium nitrite	1.00	0.40
Sulphamic acid	2.00	1.00
Sodium hydroxide	5.00	2.50






Fig. 1. An example of calibration plot of standard paracetamol samples at wavelength of 430 nm.




Fig. 2. Correlation of results for plasma paracetamol concentration measured by the present method and with HPLC reference method.

respectively. The change in the absorbance of the final solutions per minute was constant up to 10 min for all standards.

There was excellent correlation between the paracetamol concentration in the stored plasma samples by HPLC and the colorimetric method ($r^2 = 0.98$) (Fig. 2). The Bland–Altman plot for paracetamol concentrations estimated by the colorimetric method and HPLC is shown in Fig. 3.

A total of 99 (10 patients per month) paracetamol-poisoning patients were identified, of whom 74 had the paracetamol concentration measured and 43 patients were treated with NAC (Fig. 4). The measurement of a plasma paracetamol




Fig. 3. Bland and Altman plot for paracetamol measured by present method and HPLC method.

concentration was used to identify 27 (36.5% of those who had a paracetamol assay) patients who did not require NAC.

Discussion

Paracetamol poisoning results in only non-specific clinical features such as nausea and vomiting in the early stage of poisoning and the risk of liver damage is normally predicted from the plasma paracetamol concentration.^{1,2} Therefore, the estimation of plasma paracetamol concentrations is important in all patients with paracetamol poisoning to identify the severity of poisoning, the need for treatment with the antidote NAC, and to guide prognosis. 1,9 HPLC paracetamol assays are not widely available in most hospitals in Sri Lanka and South Asia and therefore risk assessment in this patient group can be problematic.6

A number of assay techniques have been assessed for paracetamol; these techniques have variable costs and different requirements for technical skill and equipment. These include colorimetric techniques, ^{8,10,11} UV spectrophotometric methods, ¹² immunoassays, ¹³ HPLC, ^{14,15} gas chromatography, ^{16,17} and electrophoresis. 18 HPLC is generally accepted as the method of choice. However, both HPLC and gas chromatography are expensive techniques with expensive equipment and high operational and maintenance costs. Some enzymatic colorimetric assays give false results in paracetamol levels, which may be due to methodological interferences of bilirubin.^{19,20} The method of Glynn and Kendal is little affected by paracetamol conjugates and gives more reliable measure of unchanged (free) drug. Previous research reports that interference by salicylates and salicylamide can occur. 21,22 Interference by salicylates, although slight, can be corrected using modifications in the method.²³ Furthermore, amitriptyline,



45




Fig. 4. Patient's treatment results based on the paracetamol levels.

amphetamine, caffeine, chlordiazepoxide, chlormezanone, chlorpromazine, chlorpropamide, cocaine, diazepam, diphenhydrainine, dihydrocodeine, imipramine, indomethacin, lorazepam, meprobamate, methadone, methaqualone, morphine, nitrazepam, oxypertine, pentazocine, pentobarbital, phenacetin, phenytoin, promethazine, strychnine, theophylline, and tolbutamide reportedly do not interfere with this method. There is no interference by NAC with the method.²⁴

The cost per test using an immunoassay method is high because of the cost of kits. The colorimetric assay method is less expensive, but it is not currently available in Sri Lanka or other areas of South Asia. In general, the cost per test using HPLC is US\$ 124 compared to less than US\$ 1 per test for a colorimetric assay. Furthermore, colorimetric techniques are more applicable to the instrumentation available and the testing frequency of small hospitals and rural treatment centers in South Asia, because of minimal reagent cost and waste.²⁵ Despite this they have not been implemented; barriers have included local validation, training, and a requirement to vent noxious gases.

We have shown that this new colorimetric assay for paracetamol is accurate, both in aqueous solution and more importantly in plasma samples from patients with paracetamol poisoning over a clinically relevant range of paracetamol concentrations. The modifications that we have introduced to the method allowed the assay to be performed without the need for a fume hood, using laboratory consumables and equipment that are widely available in Sri Lanka and other areas of South Asia. The instrument needed for the test is a spectrophotometer, which is available in many hospitals in

South Asia. The instrument cost is approximately US\$ 4,000–8,000 and the reagent cost per test is about US\$ 0.50.

In the clinical cohort study, use of the antidote NAC was avoided in over a third of patients who had the plasma paracetamol concentration measured; the availability of the colorimetric assay therefore had a significant positive impact on the management of this group of patients. Furthermore, this has the potential to have a significant economic impact. We have shown that in Sri Lanka and other areas of the developing world, the cost of NAC is the major cost in patients with paracetamol poisoning.⁶ Previous studies have shown that the introduction of an appropriately used, accurate, and costeffective paracetamol assay was a central strategy in reducing costs and improving the standard of care of these patients.⁴ Most hospitals currently have the facilities to be able to perform the colorimetric assay; therefore the additional costs of US\$ 16 (31 patients) in performing paracetamol assays would result in up to four patients avoiding unnecessary treatment with NAC and a cost saving of US\$ 576 (Fig. 4).

In countries where paracetamol poisoning is prevalent and the cost of antidote is a high component of total cost introduction of a paracetamol assay service appears cost effective and may reduce total expenditure.

Conclusion

This new colorimetric paracetamol assay is reliable, accurate, and can be performed rapidly, easily, and economically. Its



introduction into Sri Lanka and hospitals in other areas of South Asia and the developing world has the potential to have a significant impact on both the clinical and the economic perspective. This would result in an improvement in the management of an increasing clinical problem in light of the changing epidemiology of poisoning in Sri Lanka and other areas of South Asia.

Acknowledgments

The authors are very thankful and grateful to Teaching Hospital, Peradeniya, for providing research facilities and encouragement. We thank our clinical investigators, Dr. KS Kularathne, and those who provided samples and cared for study patients. We are thankful to The South Asian Clinical Toxicology Research Collaboration, which is funded by Wellcome Trust/National Health and Medical Research Council International Collaborative Research Grant GR071669MA. The funding bodies had no role in analyzing or interpreting the data or writing the manuscript. We also thank Professor R Swaminathan who arranged for the HPLC paracetamol assays to be undertaken in the Department of Chemical Pathology at Guy's and St Thomas' NHS Foundation Trust, London, UK.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

References

- 1. Daly FFS, Fountain JS, Murray L, Graudins A, Buckley NA. Guidelines for the management of paracetamol poisoning in Australia and New Zealand-explanation and elaboration. Med J Aust 2008; 188:296.
- 2. Dawson AH, Whyte IM. Therapeutic drug monitoring in drug overdose. Br J Clin Pharmacol 1999; 48:278-283.
- 3. Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, Caravati EM, Wax PM, Keyes DC, Woolf AD, Scharman EJ, Booze LL, Troutman WG. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006; 44:1-18.
- 4. Lall SB, Paul R. Paracetamol poisoning in children. Indian J Pediatr 1998; 65:393-400.
- Paudyal BP. Poisoning: pattern and profile of admitted cases in a hospital in central Nepal. JNMA J Nepal Med Assoc 2005; 44:92-96.

- 6. Senarathna SM, Ranganathan SS, Dawson AH, Buckley N, Fernandopulle BM. Management of acute paracetamol poisoning in a tertiary care hospital. Ceylon Med J 2008; 53:89-92.
- 7. Fernando R. Management of poisoning. Colombo: The National poison Information Centre, National Hospital of Sri Lanka; 2007.
- 8. Glynn JP, Kendal SE. Letter: paracetamol measurement. Lancet 1975; 1:1147-1148.
- 9. Dargan P, Jones A. Effects of legislation restricting pack sizes of paracetamol on self poisoning. It's too early to tell yet. BMJ 2001; 323:633.
- 10. Shihabi ZK, David RM. Colorimetric assay for acetaminophen in serum. Ther Drug Monit 1984; 6:449-453.
- 11. Gupta RN, Pickersgill R, Stefanec M. Colorimetric determination of acetaminophen. Clin Biochem 1983; 16:220-221.
- 12. Nagaraja P, Murthy KC, Rangappa KS. Spectrophotometric method for the determination of paracetamol and phenacetin. J Pharm Biomed Anal 1998; 17:501-506.
- 13. Egleston CV, Browning C, Hamdi I, Campbell-Hewson G, Robinson SM. Comparison of two assays for measuring plasma concentrations of paracetamol. BMJ 1997; 315:991-992.
- 14. Senyuva H, Ozden T. Simultaneous high-performance liquid chromatographic determination of paracetamol, phenylephrine HCl, and chlorpheniramine maleate in pharmaceutical dosage forms. J Chromatogr Sci 2002; 40:97-100.
- 15. Hannothiaux MH, Houdret N, Lhermitte M, Izydorczak J, Roussel P. High performance liquid chromatographic determination of paracetamol in human serum. Ann Biol Clin (Paris) 1986; 44:139-141.
- 16. Becherucci C, Runci FM, Segre G. Gas chromatographic determination of paracetamol in plasma. Farmaco 1981; 36:312-316.
- 17. Dechtiaruk WA, Johnson GF, Solomon HM. Gas-chromatographic method for acetaminophen (N-acetyl-p-aminophenol) based on sequential alkylation. Clin Chem 1976; 22:879-883.
- 18. Chu Q, Jiang L, Tian X, Ye J. Rapid determination of acetaminophen and p-aminophenol in pharmaceutical formulations using miniaturized capillary electrophoresis with amperometric detection. Anal Chim Acta 2008; 606:246-251.
- 19. Bertholf RL, Johannsen LM, Bazooband A, Mansouri V. False-positive acetaminophen results in a hyperbilirubinemic patient. Clin Chem 2003; 49:695-698.
- 20. Polson J, Wians FH, Orsulak P, Fuller D, Murray NG, Koff JM, Khan AI, Balko JA, Hynan LS, Lee WM, Acute Liver Failure Study Group. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008; 391:24-30.
- 21. Archer CT, Richardson RA. An improved colorimetric method for the determination of plasma paracetamol. Ann Clin Biochem 1980;
- 22. Longlands MG, Wiener K. Minimisation of salicylate interference in the Glynn and Kendal paracetamol procedure. Ann Clin Biochem 1982; 19:187-190.
- 23. Buttery JE, Braiotta EA, Pannall PR. Plasma acetaminophen results are method dependent. J Toxicol Clin Toxicol 1982; 19:1117-1122.
- 24. Bridges RR, Kinniburgh DW, Keehn BJ, Jennison TA. An evaluation of common methods for acetaminophen quantitation for small hospitals. J Toxicol Clin Toxicol 1983; 20:1-17.
- 25. Bailey DN. Colorimetry of serum acetaminophen (paracetamol) in uremia. Clin Chem 1982; 28:187-190.

